IP10级别在TDF治疗挂钩的HBsAg下降

StephenW

IP10 levels linked to HBsAg decline during TDF treatment
Published on August 4, 2015 at 5:15 PM · No Comments

   

By Shreeya Nanda, Senior medwireNews Reporter

Baseline serum interferon-inducible protein 10 (IP10) levels predict hepatitis B surface antigen (HBsAg) reduction in patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B virus (HBV) infection treated with tenofovir disoproxil fumarate (TDF), findings indicate.

These results suggest that “IP10 levels can have clinical implications in the management of [chronic HBV] and may lead to novel immunomodulatory approaches”, says the team led by George Papatheodoridis (Athens University Medical School, Greece).

Among the 160 chronic HBV patients who started TDF therapy between 2008 and 2012, HBsAg levels reduced by a median of 0.08, 0.11, 0.24, 0.33 and 0.38 log10 IU/mL at 6, 12, 24, 36 and 48 months, respectively, relative to baseline. There were no significant changes between the 78 patients who had and the 82 patients who had not previously received nucleos(t)ide analogue (NA) treatment.

At the final assessment, 25% and 12% of all study participants attained a minimum 0.5 log10 IU/mL and 1.0 log10 IU/mL reduction in HBsAg levels, respectively.

And the cumulative rates of at least a 0.5 log10 IU/mL decline in HBsAg levels at 12, 24, 36 and 48 months were 8%, 16%, 24% and 41%, respectively. The corresponding rates for a minimum 1.0 log10 IU/mL decline in HBsAg levels were 4%, 10%, 12% and 15%.

In univariate analysis, both baseline HBsAg and IP10 levels were significantly associated with HBsAg reduction of at least 0.5 log10 IU/mL (p=0.004 and p=0.002, respectively), but in multivariate analysis, the association remained significant only for serum IP10 levels (p≤0.001).

Using a previously reported IP10 cutoff of 350 pg/dL, Papatheodoridis et al found that patients with baseline IP10 levels above compared with below the cutoff achieved HBsAg reduction of at least 0.5 log10 IU/mL significantly earlier (p<0.001).

“As HBV can limit the induction of antiviral defence mechanisms in the liver and higher serum IP10 levels probably reflecting an activated immune system are associated with favourable responses in [chronic HBV] patients, induction of IP-10 could represent a potential novel immunomodulatory approach in the treatment of [chronic HBV], as it has been recently tried in other diseases”, the researchers write in the Journal of Viral Hepatitis.

They add: “Additional evaluation of the usefulness of serum IP10 levels in [chronic HBV] patients who achieve HBsAg loss under long-term NA therapy will be of great interest.”

Licensed from medwireNews with permission from Springer Healthcare Ltd. ©Springer Healthcare Ltd. All rights reserved. Neither of these parties endorse or recommend any commercial products, services, or equipment.

StephenW

IP10级别在TDF治疗挂钩的HBsAg下降
发表于2015年8月4日在5:15 PM·没有评论

   

通过Shreeya南大，高级medwireNews记者

基线血清干扰素诱导蛋白10（IP10）水平预测乙肝表面抗原（HBsAg）减少患者的乙型肝炎e抗原（HBeAg）阴性慢性乙型肝炎病毒（HBV）感染与富马酸替诺福韦酯（TDF）治疗，结果表示。

这些结果表明，“IP10等级可以在[慢性HBV]管理临床意义，并可能导致新型免疫调节办法”说，带领乔治Papatheodoridis（雅典大学医学院，希腊）的团队。

其中160慢性乙肝患者谁开始2008年和2012年间TDF治疗，HBsAg水平分别降低了0.08，0.11，0.24，0.33和0.38中位日志10 IU / mL的6，12，24，36和48个月，相对基线。有78例谁和谁没有以前收到的核苷（酸）类似物IDE（NA）治疗的82例患者之间没有显著的变化。

在最后的评估，25％和所有研究参与者的12％达到最低0.5日志10 IU / mL和1.0日志10 IU / mL的减少HBsAg水平，分别为。

和至少0.5日志10 IU /毫升下降HBsAg水平在12，24，36和48个月的累积率分别为8％，16％，24％和41％，分别为。最少1.0日志10 IU /毫升下降HBsAg水平相应率分别为4％，10％，12％和15％。

在单因素分析，基线HBsAg和IP10水平显著与乙肝表面抗原至少减少0.5日志10 IU / mL的相关（P = 0.004和p = 0.002，分别），但在多变量分析，该协会只针对血清IP10水平仍然显著（P≤0.001）。

使用先前报道的350微克/ dL的IP10截止，Papatheodoridis等人发现患者基线IP10水平高于与截止低于相比达到至少0.5日志10 IU /毫升的HBsAg还原显著较早（P <0.001）。

“作为HBV可以限制在肝脏抗病毒防御机制和较高的血清IP10水平可能反映激活的免疫系统的诱导与在[慢性HBV]患者有利应答相关联，感应的IP-10可能代表在一个潜在的新的免疫调节的方法[慢性HBV]的治疗，因为它已经在其他疾病“最近出现过，研究人员写道病毒性肝炎杂志。

他们补充说：“血清IP10水平[慢性HBV]病人谁下实现长期NA治疗乙肝表面抗原的损失将是极大的兴趣的实用性评价其他。”

从medwireNews与施普林格医疗保健用品有限公司©斯普林格保健有限公司保留所有权利许可授权。无论这些政党的认可或推荐任何商业产品，服务或设备。